Pulmonary Medicine Research and Innovation

Benjamin Kopp, MD

Which Patients With Cystic Fibrosis Will Respond Best to Lumacaftor/Ivacaftor?

This common drug combination is associated with changes in lipid and amino acid metabolic pathways, raising the possibility of biomarkers to predict clinical response.


Sleep-Disordered Breathing and Cardiovascular Issues in Children

Sleep-disordered breathing affects the heart, but cardiovascular complications can also affect sleep.

A Potential Biomarker for Lung Disease in Cystic Fibrosis

A microRNA cluster is elevated in cystic fibrosis sputum and associated with pulmonary exacerbations.

Could Earlier Spirometry Get CF Inpatients Home Sooner?

Checking spirometry earlier may help reduce length of stay those with cystic fibrosis pulmonary exacerbations.

Fostering Disease-Specific Expertise Outside of Pulmonology: The CF/GI Combined Clinic

Pulmonologists and gastroenterologists have teamed up to treat CF patients in a single visit, with on-the-spot consultation and treatment plans created by the joint clinician team.

Clinical Benefits Found for Pediatric Asthma Patients in a Pulmonary Rehab Program

FEV1, shortness of breath score and physical quality of life were all improved after participation in a formalized program.

Heart and Lungs

Current Pediatric Lung Transplant Trends

CF patients are more often requiring lung transplants later in life while there is a growing trend in children with refractory ARDS needing transplants.

Additional Research

Asthma Research

In 1999, the Section of Pulmonary Medicine at Nationwide Children’s was designated as an American Lung Association Asthma Clinical Research Center, one of 18 selected participants, only five of which are pediatric.

Cystic Fibrosis Research

Pulmonary Medicine at Nationwide Children’s Hospital has been involved in research related to cystic fibrosis (CF) since the early 1990s.